ADOCIA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.63 EUR | +0.23% |
|
+1.89% | -25.22% |
| Apr. 24 | Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 22 | Adocia: announces fund-raising | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2023 | 6.05M 6.52M | Sales 2024 * | 50M 53.88M | Capitalization | 123M 133M |
|---|---|---|---|---|---|
| Net income 2023 | -21M -22.63M | Net income 2024 * | 26M 28.02M | EV / Sales 2023 | 26.8 x |
| Net Debt 2023 * | 3.3M 3.56M | Net cash position 2024 * | 22.5M 24.25M | EV / Sales 2024 * | 2.01 x |
| P/E ratio 2023 |
-6.07
x | P/E ratio 2024 * |
2.31
x | Employees | 97 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 95.08% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.58% | ||
| 1 week | +1.06% | ||
| Current month | +2.39% | ||
| 1 month | -6.45% | ||
| 3 months | -15.42% | ||
| 6 months | +6.34% | ||
| Current year | -25.82% |
1 week
8.31
9.28
1 month
7.899.31
Current year
7.8912.40
1 year
3.1116.16
3 years
2.7516.16
5 years
2.7522.60
10 years
2.7594.24
| Managers | Title | Age | Since |
|---|---|---|---|
Olivier Soula
FOU | Founder | 53 | 05-12-15 |
Gérard Soula
FOU | Founder | 78 | 05-12-15 |
| Director of Finance/CFO | - | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gérard Soula
FOU | Founder | 78 | 05-12-15 |
| Director/Board Member | 67 | 21-05-20 | |
| Director/Board Member | 58 | 13-06-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 8.63 | +0.23% | 40 930 |
| 24-05-09 | 8.61 | -4.33% | 79,673 |
| 24-05-08 | 9 | +6.89% | 162,354 |
| 24-05-07 | 8.42 | +0.60% | 32,816 |
| 24-05-06 | 8.37 | -1.18% | 24,362 |
Real-time Euronext Paris, May 10, 2024 at 09:39 am EDT
More quotes
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes.
At the end of 2023, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram-ADO09 and BioChaperone Glucagon) and 3 preclinical-stage products (BioChaperone® LisPram, BioChaperone® Glargine GLP-1 and BioChaperone® Glucagon GLP-1).
Calendar
2024-05-12
- Equity Spring Forum
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8.61
EUR
Average target price
9.7
EUR
Spread / Average Target
+12.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.82% | 133M | |
| +2.97% | 108B | |
| +10.21% | 104B | |
| +3.32% | 22.33B | |
| -12.77% | 22.19B | |
| -7.05% | 18.69B | |
| -38.36% | 17.74B | |
| -6.50% | 17.64B | |
| +6.00% | 14.05B | |
| +37.20% | 12.51B |
- Stock Market
- Equities
- ADOC Stock